key: cord-1001712-n40rgbq9
authors: Alsaffar, Welaia A; Alwesaibi, Albatool A; Alhaddad, Mousa J; Alsenan, Zainab K; Alsheef, Hawra J; Alramadan, Saleh H; Aljassas, Hassan A; Alsaghirat, Mohammed A; Alzahrani, Hassan J
title: The Effectiveness of COVID-19 Vaccines in Improving the Outcomes of Hospitalized COVID-19 Patients
date: 2022-01-22
journal: Cureus
DOI: 10.7759/cureus.21485
sha: a1dec409bc377cd4baab2c72689bd3208cf0ab5f
doc_id: 1001712
cord_uid: n40rgbq9

Background With the rapid spread of coronavirus disease 2019 (COVID-19), most countries took extreme measures to control the disease. Equitable access to safe and effective vaccines is critical to ending the COVID-19 pandemic. The Ministry of Health program in Saudi Arabia aimed to cover 17.4 million adults (70% of the adult population of Saudi Arabia) by the third quarter of 2021. We investigated the impact of the COVID-19 vaccine on the clinical course and outcomes of the admitted confirmed COVID-19 patients, in comparison to non-vaccinated patients. Methodology A retrospective cross-sectional record review was conducted for all hospitalized confirmed COVID-19 patients at Dammam Medical Complex (Eastern Province, Saudi Arabia) from June to July 2021. Two groups were studied according to the vaccination status (i.e., vaccinated and non-vaccinated). Information regarding comorbidities, length of stay, high oxygen requirements, ICU admission, and mortality data were collected and analyzed using the Python programming language (version 3.7.6) with the use of SciPy library (1.4.1) and Statsmodels module (v0.11.1). Results The sample included a total of 260 admitted confirmed COVID-19 cases. The mortality was significantly lower in the vaccinated group versus the non-vaccinated group with an odds ratio (OR) of 0.378 (CI 0.154-0.928). In addition, the OR of ICU admission was 0.476 (CI 0.218-1.042) and OR of endotracheal intubation was 0.561 (CI 0.249-1.265), but these did not reach statistical significance. We also detected a statistically significant relationship between mortality - regardless of vaccination status - and age ≥ 65 years (P=0.000, OR=7.51; 95%CI 3.13 to 18.04), chronic kidney disease (P=0.010, OR=5.62; CI 1.52 to 20.79), and renal transplant (P=0.037, OR=10.17; CI 1.15 to 89.76). Of note, most of our vaccinated patients received only a single dose (85%). Conclusion There is a significant reduction in mortality cases as well as less complicated hospital courses among the vaccinated group, in spite of the fact that most of our admitted patients had only a single vaccine shot. Suboptimal response to the vaccines was observed in the elder, chronic kidney disease, and renal transplant patients, hence the poorer outcomes in comparison to other patients.

Understanding of the coronavirus disease 2019 (COVID-19) is evolving; the extent of the spread and the severity of illness prompted widespread attempts to identify and recognize the nature of the disease. Rapid identification and sequencing of the virus allowed scientists -with the help of research centers and biotechnical companies -to begin developing preventive vaccines quickly. Vaccination is now considered the most promising approach for ending or containing the coronavirus disease 2019 (COVID-19) pandemic [1] . COVID19 vaccine development had progressed through preclinical evaluation and underwent three clinical phase trials. Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines have shown high efficacy against disease in phase 3 clinical trials and are now being used in national vaccination programs in the UK 1 1 1 1 1 and several other countries [2, 3] . In the United States, Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines have been granted emergency use authorization (EUA) for the prevention of COVID-19 [4, 5] . They are all effective at preventing and reducing the risk of different variants of the COVID-19 virus, especially the severe form of the disease [6, 7] . They are also valuable and proven to be safe in the elderly, frail, immunosuppressed, and vulnerable nursing home populations [8] [9] [10] . The Pfizer/BioNTech provides immunogenicity for at least 119 days after the first vaccination [11] . A two-dose regimen of Pfizer/BioNTech vaccine had 95% efficacy (95% CI 90.3-97. 6 ) in preventing symptomatic COVID-19 at or after day 7 following the second dose in placebo-controlled multinational trials [12] . On August 23, 2021, the US Food and Drug Administration approved the first COVID-19 vaccine, which is Pfizer/BioNTech. The mass roll-out of the first doses of the Pfizer/ BioNTech and Oxford-AstraZeneca vaccines was associated with substantial reductions in the risk of hospital admission due to COVID-19 in Scotland. In the prospective cohort study, the first dose of the Pfizer/ BioNTech vaccine was associated with a vaccine effect of 91% (95% CI 85-94) for reduced COVID-19 hospital admission at 28-34 days post-vaccination. Vaccine effect at the same time interval for the Oxford -AstraZeneca vaccine was 88% (95% CI 75-94) [13] . Saudi authorities established a system responsible for continually monitoring national and international updates, raising awareness, and taking proper actions to contain the spread of this disease. 

Dammam Medical Complex (IRB) has approved the protocol and issued approval IM-01 after careful review. Approval is given for one year from the date of this letter (July 9, 2021). This is to confirm that DMC IRB operated in accordance with NCBE regulations and ICH GCP E6 R2.

We conducted a retrospective record review of all consecutive hospitalized patients in Dammam Medical Complex (Eastern Province, Saudi Arabia), who had tested positive for COVID-19 by polymerase chain reaction (PCR).

All confirmed COVID-19 patients aged 18 and older were admitted to Dammam Medical Complex from June to July 2021.

We used the patient's medical record numbers (MRNs) to collect the data from the electronic hospital system: patient's age, gender, presence or absence of chronic diseases (e.g., diabetes mellitus, hypertension, heart disease, lung disease, BMI, and cancer), oxygen requirement, intubation, ICU admission, hospital length of stay, and disposition. The study was approved by the Institutional Review Board of Dammam Medical Complex.

We divided the patients into two groups according to their vaccination status. Individuals who received at least one dose of COVID-19 vaccine (BNT162b2 or Oxford-AstraZeneca) were placed in the "vaccinated group"; individuals who did not receive any vaccine dose were placed in the "non-vaccinated group." In addition, the date of vaccination, number of doses, and the date of acquiring the infection were obtained.

The data were analyzed using the Python programming language (version 3.7.6) with the use of the SciPy library (1.4.1) and Statsmodels module (v0.11.1). Descriptive statistics (i.e., mean, standard deviation, count, and percentage) were calculated as necessary. Categorical variables were compared with the Chisquare test and continuous variables were compared with the two-sample t-test. Multivariate logistic regression models were created with death, intubation, ICU admission, and the need for high supplementary oxygen (10 L or more) or ventilation support as dependent variables. The models were adjusted for the male sex, age of 65 years or above, vaccination status, and major comorbid conditions (including diabetes mellitus, hypertension, bronchial asthma, chronic kidney disease, active cancer, and history of kidney transplantation). The odds ratios and confidence intervals were reported. A p-value of less than 0.05 was assumed to indicate statistical significance. All data were used only for research purposes.

The clinical characteristics of the patients are presented in Table 1 . The records from a total of 260 patients with confirmed COVID-19 infection were analyzed, with a mean age of 51.72 ±15.1 years. Only 37.69% (n=98) received a COVID-19 vaccine; of them, only 5.77% (n=15) had two shots of the vaccine. Roughly half (58.85%) of the sample were males. The most common comorbidities were diabetes mellitus (40.0%, n=104), hypertension (36.15%, n=94), and morbid obesity (27.31%, n=71). Other chronic conditions include heart disease, chronic kidney disease, and obstructive lung diseases (11.15%, 7.69%, and 7.31%, respectively). Our study also included a small number of immunocompromised patients who had been diagnosed with an oncological disease (2.69%, n=7), and those who underwent solid organ transplantation (2.69%, n=7). To assess the outcomes among each patient's characteristics listed in Table 3 

Due to our small sample size, we demonstrated no statistical significance regarding mortality in the vaccinated and non-vaccinated patients in the subgroup analysis shown in Table 4 . 

In our retrospective cross-sectional study, we evaluated the impact of COVID-19 vaccination and its effectiveness in the inpatient setting, in terms of decreasing mortality, the need for ICU admission, intubation, and high oxygen demand related to severe COVID-19 infection. We investigated 260 hospitalized confirmed COVID-19 patients, with various demographic and comorbidity profiles. One hundred and sixtytwo (62.31%) of them were not vaccinated, and 98 (37.69%) were vaccinated. Out of the vaccinated group only 15 patients (5.77%) received two doses of the vaccine.

In the current study, we found that even a single vaccine dose is effective in preventing severe COVID-19 infection-related consequences, the adjusted odds ratio of death in the vaccinated group was 0.39 (CI is 0.15 to 0.93). The percentages of survival after single and two doses were 88% (73 out of 83 patients), and 80% (12 out of 15 patients), respectively. Of note, the majority of those who received two doses were diabetic, elderly, and renal transplant groups.

A case-control study conducted in England analyzed 156,930 adults aged 70 years and older showed that the BNT162b2 vaccine effects after the first dose, reached 70% (95%CI 59% to 78%), after the second dose vaccination effectiveness of 89% (85% to 93%). For the Oxford-AstraZeneca vaccine, effects were seen from 14 to 20 days after vaccination, reaching effectiveness of 60% (41% to 73%) from 28 to 34 days increasing to 73% (27% to 90%) from day 35 onwards [17] .

Another case-control study done in Qatar showed that the effect was negligible in the first two weeks after the first dose. It increased to 36.8% (95% CI, 33.2 to 40.2) in the third week after the first dose and reached its peak at 77.5% (95% CI, 76.4 to 78.6) after the second dose [18] .

The risk of severe COVID-19 illness increases with age; this is why the CDC recommends that adults older than 65 years have the priority for receiving COVID-19 vaccines.

In our analysis, out of 260, only 51 (20%) patients aged 65 years and older were admitted with COVID-19 infection. 64.7% (n=33) of them were unvaccinated, death reported to be 54.55% (n=18) in this group. years was estimated to be 96% (95% CI = 94%-98%) and 84% (95% CI = 76%-89%), respectively. The efficacy in those aged ≥75 years was noted to be lower; 91% (95% CI = 87%-94%) and 66% (95% CI = 48%-77%) following full and partial vaccination, respectively [19] . This proves the high efficacy of full as well as partial vaccination in preventing hospitalization in the old population. 

Very few data are available regarding vaccine safety and efficacy in patients with immunocompromising conditions, such as cancer, or who take immunosuppressive therapies. The available data on the BNT162b2 vaccine in cancer patients suggest that vaccination is safe, but efficacy may be compromised, especially in those with hematologic malignancies. A prospective observational study included 151 patients with cancer (95 with a solid tumor and 56 with a hematologic malignancy), and 54 healthy controls without cancer, assessing the safety and immunogenicity of the BNT162b2 in patients with cancer and healthy controls. In the cancer group, one dose of the BNT162b2 vaccine yielded poor efficacy. However, a remarkable increase was observed in immunogenicity in patients with solid cancer within two weeks of a vaccine boost at day 21 after the first dose [22] . Several other studies showed similar results of suboptimal vaccine response in patients with hematologic malignancies [23] [24] [25] .

In our study, the sample was small, hence, we could not accurately assess the mortality. We recruited a total of seven patients with cancer on immunosuppression therapy. Only two of these were vaccinated and both were discharged home in good condition, while two unvaccinated patients died.

Our study included only seven post-organ transplant patients (six kidneys and one liver) who were on active immunosuppressive therapy, six out of which were vaccinated (two of them received two doses). Unfortunately, three of the vaccinated group died, with an estimated mortality odds ratio of 10.166 (CI 1.151 to 89.755). This implies the efficacy of the vaccine on the transplantation population might be poor, whether after a single or two doses. The low vaccine efficacy among this group of patients is highly correlated to the minimal immune response following the vaccine, and this could be explained by the aggressive immunosuppressive therapies, low eGFR, and being elderly. One study done in France analyzed 101 postsolid organ transplant patients showed that the prevalence of the anti-COVID-19 antibodies that should be acquired after the vaccination was only 4% (95% CI, 1 to 10; four of 101 patients) after the first dose of vaccine, and 40% (95% CI, 31 to 51; 40 of 99 patients) following the second dose. However, four weeks after the third dose it reached up to 68% (95% CI, 58 to 77; 67 of 99 patients), indicating a significant improvement in immunogenicity following the booster third dose [26, 27] .

Obesity is one of the comorbidities leading to the development of other chronic diseases, and hence, was found to be a recognized risk for severe COVID-19 infection. One theory attributed this to the presence of the ACE2 receptors in many adipose tissues, which serve as the access point for the virus to enter human cells leading to a higher viral load and a long time of viral clearance. Moreover, it increases inflammatory cytokines which contribute to more severe infection [28, 29, 30] . In our study, 25 vaccinated patients labeled as obese with body-mass index (BMI) of ≥ 30 kg/m 2 , 24% (n=6) died. Of note, most of the dead patients were older than 65 years, were post-renal transplantation, or had other comorbidities, such as renal impairment and diabetes mellitus. A retrospective cohort study was conducted in France on 124 obese patients showed a correlation between the need for invasive mechanical ventilation due to severe COVID-19 infection and obesity with a BMI of 30 kg/m 2 and higher [31] . To date, we are lacking data regarding the effectiveness of COVID-19 vaccination in an obese population. In a multinational, placebo-controlled trial, the BNT162b2 was 95% effective in preventing COVID-19 (95% CI; 90.3 to 97.6). Similar vaccine efficacy was observed across subgroups, including patients with BMI ≥ 30.0 kg/m 2 [12] . Thus, this group of patients should be encouraged to get vaccinated against COVID-19 infection.

Whether the use of high-flow oxygen in patients with COVID-19 associated with acute respiratory failure improves clinically relevant outcomes remains unknown [32] . Out of 260 COVID-19 positive patients, only 104 patients required either invasive or non-invasive mechanical ventilation or 10 L or more of supplemental oxygen. However, the use of high-flow oxygen was shown to be more necessitated in the unvaccinated group than in the vaccinated group; 69 unvaccinated patients (42.59%) required high-flow oxygen, compared to only 35 vaccinated patients (35.71%). The vaccinated group showed less demand for high-flow oxygen than did the unvaccinated group. Critically ill COVID-19 patients in the emergency department or on the general ward were transferred to ICU for critical close monitoring or intervention. 

Considering the transmissible nature of COVID-19, the epidemiological data report fluctuation, especially in the mortality rate. In Saudi Arabia, the incidence of COVID-19 and the mortality rate have been gradually declining, reflecting the implementation of successful preventive measures, and effective healthcare practices and treatment protocols.

As for our study analysis, reported deaths were 48 COVID-19 positive patients, of whom 35 patients (21.6%) were unvaccinated, while 13 patients (13.27%) were vaccinated either by one dose or the full dose.

A study by Bernal et al. showed evidence of the effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-Astra-Zeneca ChAdOx1-S vaccinations against symptomatic COVID-19 disease, hospitalization, and death in the older population. The vaccinated group had a 44% decreased risk of hospitalization and a 51% lower risk of death compared to the unvaccinated group [17] .

There are multiple limitations to our study. First, it was conducted only at one health center for a two-month duration, hence the small sample size. Furthermore, our sample did not include a good number of transplant and cancer patients.

Having only 98 vaccinated patients requiring hospital admission, compared to the huge number of vaccinated people in the region, implies the positive impact of the COVID-19 vaccine in preventing the infection as well as decreasing the severity of symptoms, and therefore the need for hospitalization. In our study, we demonstrated a statistically significant reduction in fatality among the vaccinated group, where even a single dose was effective in preventing major sequels.

We determined the vaccine effectiveness by having a mild hospital course, in terms of requiring less airway and oxygen support, endotracheal intubation, ICU care, and lower mortality rates. A reduced efficacy and poor response were observed in the elderly and those with chronic kidney disease and a history of renal transplant. Ultimately, we advise vaccination against COVID-19 infection for all eligible patients in keeping with the FDA recommendation.

Human subjects: Consent was obtained or waived by all participants in this study. Dammam Medical Complex (DMC) issued approval IM-01. DMC IRB has approved the protocol after careful review. Approval is given for one year from the date of this letter (July 9, 2021). This is to confirm that DMC IRB operated in accordance with NCBE regulations and ICH GCP E6 R2. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

The rapid development and early success of COVID 19 vaccines have raised hopes for accelerating the cancer treatment mechanism

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19

Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants

Age and frailty in COVID-19 vaccine development

Incident Sars-COV-2 infection among mRNA-vaccinated and unvaccinated nursing home residents

The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data

COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

MOH: COVID-19 vaccine to be received in phases

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar

Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged ≥65 years -Covid-Net, 13 States

COVID-19 vaccination for people with comorbidities

Vaccines and related biological products advisory committee meeting. Pfizer-BioNTech COVID-19 Vaccine

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Antibody response to COVID-19 vaccination in adults with hematologic malignant disease

Humoral immune response in hematooncological patients and healthcare workers who received SARS-COV-2 vaccinations

A: Three doses of an mRNA COVID-19 vaccine

in solid-organ transplant recipients

Antibody response after third mRNA-1273 SARS-COV-2 vaccine dose in kidney transplant recipients with minimal serologic response to 2 doses

A time frame for testing negative for SARS-COV2 in people with obesity

The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections

Vaccinating people with obesity for COVID-19: EASO call for action

High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) requiring invasive mechanical ventilation

High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure

Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings